Literature DB >> 16866005

Use of neural response telemetry measures to objectively set the comfort levels in the Nucleus 24 cochlear implant.

John E King1, Marek Polak, Annelle V Hodges, Stacy Payne, Fred F Telischi.   

Abstract

Cochlear implant programming necessitates accurate setting of programming levels, including maximum stimulation levels, of all active electrodes. Frequently, clinical techniques are adequate for setting these levels; however, they are sometimes insufficient (e.g., very young children). In the Nucleus 24, several methods have been suggested for estimation of comfort levels (C levels) from neural response telemetry (NRT); however, many require co-application of clinical measurements. Data was obtained from 21 adult Nucleus 24 recipients to develop reliable predictions of C levels. Multiple regression analysis was performed on NRT threshold, slope of the NRT growth function, age, length of deafness, length of cochlear implant use and electrode impedance to examine predictive ability. Only the NRT threshold and slope of the growth function measures were significant predictors yielding R2 values from 0.391 to 0.769. Results demonstrated that these measures may provide an alternative means of estimating C levels when other clinical measures are unavailable.

Entities:  

Mesh:

Year:  2006        PMID: 16866005     DOI: 10.3766/jaaa.17.6.4

Source DB:  PubMed          Journal:  J Am Acad Audiol        ISSN: 1050-0545            Impact factor:   1.664


  2 in total

1.  TNRT profiles with the nucleus research platform 8 system.

Authors:  W K Lai; N Dillier; B P Weber; T Lenarz; R Battmer; B Gantz; C Brown; N Cohen; S Waltzman; M Skinner; L Holden; R Cowan; P Busby; M Killian
Journal:  Int J Audiol       Date:  2009       Impact factor: 2.117

2.  Long-term evolution of the electrical stimulation levels for cochlear implant patients.

Authors:  Jose Luis Vargas; Manuel Sainz; Cristina Roldan; Isaac Alvarez; Angel de la Torre
Journal:  Clin Exp Otorhinolaryngol       Date:  2012-11-13       Impact factor: 3.372

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.